EQT Life Sciences leads Tubulis' €128 Million Financing Round

EQT Life Sciences has co-led a €128 million ($139 million) Series B2 financing round for Tubulis, a biotechnology company developing antibody-drug conjugates (ADCs) for solid tumors. The round, one of the largest in European healthcare this year, was also backed by Nextech Invest, Frazier Life Sciences, and Deep Track Capital.

The capital infusion is earmarked to advance Tubulis' lead ADC candidates, TUB-040 and TUB-030, into clinical trials. Further development of the company's technology platforms and expansion into the US market are also planned.

Founded in 2019, Tubulis aims to enhance the efficacy and safety of ADCs, a class of cancer therapies designed to target tumor cells while sparing healthy tissue. The company utilizes proprietary technologies to create customized ADCs with improved stability and effectiveness.

Christoph Broja, Managing Director at EQT Life Sciences, and Kanishka Pothula, Managing Partner at Nextech Invest, will join Tubulis' Supervisory Board following the investment.